---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-002887"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T23:35:51.739234+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Celldex reports Q1 2023 net loss $29.4M; advances barzolvolimab Phase 2 studies

## Summary
- Q1 2023 net loss $29.4M ($0.62/share); revenue $1.0M (vs $0.2M prior year).
- Cash, equivalents & securities $278.4M at March 31, 2023; sufficient through 2025.
- Phase 2 CSU enrollment completion expected Q3 2023; topline data late 2023/Q1 2024.
- Phase 2 EoE study initiation expected June 2023; CDX-585 enters clinic mid-2023.
- R&D expenses $26.8M (up from $17.1M) driven by barzolvolimab trials and manufacturing.

## SEC filing metadata
- accession: 0001171843-23-002887
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184323002887/0001171843-23-002887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184323002887/f8k_050423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-002887
- JSON: https://secwatch.observer/filing/0001171843-23-002887.json
- Plain text: https://secwatch.observer/filing/0001171843-23-002887.txt

## Key facts
- Earnings Releases
  Celldex Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000117184323002887/0001171843-23-002887-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.